About: Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland
Creator	Vesikari, Timo Salminen, Marjo Renko, Marjo Bricout, Hélène Hartwig, Susanne Hemming-Harlo, Maria Simondon, Francois Torcel-Pagnon, Laurence Uhari, Matti
Source	Medline; PMC
abstract	KEY POINTS: The effectiveness of pentavalent rotavirus vaccine against rotavirus-associated hospitalization was more than 90% 4 years after introduction into the national immunization program in Finland. A major impact on hospitalization for all-cause gastroenteritis was observed also. BACKGROUND: Rotavirus vaccination with exclusive use of RotaTeq was added to the National Immunization Programme (NIP) of Finland in September 2009. The objective of our study was to estimate the effectiveness and impact of RotaTeq after 4 years of follow-up. METHODS: Between 2009 and 2013, we conducted a prospective surveillance study of children aged <16 years with acute gastroenteritis (AGE) and admitted in 2 hospitals in Finland. Rotavirus and other gastroenteritis viruses were detected in stool samples by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assays. The effectiveness of RotaTeq was investigated by using a case-control design; wild-type rotavirus-positive children were classified as “cases” and rotavirus-negative children as “controls.” Hospital discharge records were used to estimate the impact of RotaTeq on rotavirus-associated AGE (RV-AGE) and all-cause AGE (AC-AGE) hospitalizations of age-eligible children in the NIP by comparing the prevaccination (2001–2006) and post-NIP seasons (2009–2013). RESULTS: The crude estimate of the effectiveness of RotaTeq to prevent RV-AGE hospitalization in NIP age-eligible children was 94.4% (95% confidence interval, 79.8%–98.4%). No change in prevalent wild-type rotavirus genotypes was observed. Vaccine-derived rotaviruses were detected in 8% of the children with RV-AGE, with a probable causal association in 2 children. Hospital discharge records revealed that RV-AGE and AC-AGE hospitalizations in children aged <16 years decreased in the two post-NIP seasons by 79% and 58%, respectively, compared to those in the prevaccination seasons. CONCLUSIONS: Over 4 years of follow-up, high rotavirus vaccine coverage in the NIP (>95%) has led to a major reduction in RV-AGE and AC-AGE hospitalizations without a resurgence of rotavirus activity. However, rotavirus continues to circulate in older unvaccinated children.
has issue date	2016-10-19(xsd:dateTime)
bibo:doi	10.1093/jpids/piw061
bibo:pmid	27760800
has license	no-cc
sha1sum (hex)	69ef921d1d1fc43f4f1773712e80c6da957ba219
schema:url	https://doi.org/10.1093/jpids/piw061
resource representing a document's title	Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland
has PubMed Central identifier	PMC7107484
has PubMed identifier	27760800
schema:publication	J Pediatric Infect Dis Soc
resource representing a document's body	covid:69ef921d1d1fc43f4f1773712e80c6da957ba219#body_text
is schema:about of	named entity 'Finland' named entity 'During' covid:arg/69ef921d1d1fc43f4f1773712e80c6da957ba219 named entity '2009' named entity 'RotaTeq' named entity 'Tampere' named entity 'follow-up' named entity 'RT-PCR' named entity 'consent form' named entity 'statistically significant' named entity '12.2' named entity 'wtRV' named entity 'wtRV' named entity 'genotypes' named entity 'rotavirus vaccination' named entity 'capsid protein' named entity 'genotypes' named entity 'RotaTeq' named entity 'Pirkanmaa Hospital District' named entity 'G-type' named entity 'prospective study' named entity 'respiratory diseases' named entity 'rotavirus vaccines' named entity 'Vaccine' named entity '95% CI' named entity 'gene' named entity 'rotavirus' named entity '78.6%' named entity 'nucleotide' named entity 'rotavirus' named entity 'viruses' named entity 'prospective study' named entity 'RV1' named entity 'vaccine effectiveness' named entity 'prospective study' named entity 'statistically significant' named entity 'genotype' named entity 'MSD' named entity 'rotavirus vaccination' named entity 'Merck' named entity 'Sanofi Pasteur' named entity 'wtRV' named entity 'prospective study' named entity 'rotavirus' named entity 'G1P' named entity 'wtRV' named entity 'genotypes' named entity 'genotypes' named entity 'genotype' named entity 'RT-PCR' named entity 'vaccine' named entity 'United Kingdom' named entity 'genotype' named entity 'follow-up' named entity 'G3P' named entity 'age distribution' named entity 'G1P' named entity 'wtRV' named entity 'wtRV' named entity '95% CI' named entity 'Finland' named entity 'young children' named entity 'causally related' named entity 'genotype' named entity 'Tampere University Hospital' named entity 'Finland' named entity 'Nucleotide' named entity 'rotavirus' named entity 'Finland' named entity 'rotavirus' named entity 'Australia' named entity 'rotavirus' named entity 'wtRV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software